Unknown

Dataset Information

0

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study.


ABSTRACT: Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects of indacaterol 150 ?g on lung hyperinflation compared with placebo and open-label tiotropium 18 ?g. We measured physical activity during treatment with indacaterol 150 ?g and matched placebo.We performed a randomized, three-period, cross-over study (21 days of treatment separated by two wash-out periods of 13 days) with indacaterol 150 ?g or matching placebo and tiotropium 18 ?g. Lung function was assessed by body plethysmography and spirometry. Physical activity was measured for one week by a multisensory armband at the end of both treatment periods with indacaterol/matched placebo. The primary endpoint was peak inspiratory capacity at the end of each treatment period.129 patients (mean age, 61 years; mean post-bronchodilator FEV1, 64%), were randomized and 110 patients completed the study. Peak inspiratory capacity was 0.22 L greater with Indacaterol at day 21 compared to placebo (p?

SUBMITTER: Watz H 

PROVIDER: S-EPMC4197315 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study.

Watz Henrik H   Krippner Felix F   Kirsten Anne A   Magnussen Helgo H   Vogelmeier Claus C  

BMC pulmonary medicine 20141004


<h4>Background</h4>Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects of indacaterol 150 μg on lung hyperinflation compared with placebo and open-label tiotropium 18 μg. We measured physical activity during treatment with indacaterol 150 μg and matched placebo.<h4>Methods</h4>We performed a randomized, three-period, cross-over study (21 days of treatment separated by two wash-out periods of 13 days) with indacaterol 150 μg or matching placebo a  ...[more]

Similar Datasets

| S-EPMC4908762 | biostudies-literature
| S-EPMC4077042 | biostudies-other
| S-EPMC3341383 | biostudies-literature
| S-EPMC8227740 | biostudies-literature
| S-EPMC2731764 | biostudies-literature
| S-EPMC10277723 | biostudies-literature
| S-EPMC10988878 | biostudies-literature
| S-EPMC4731943 | biostudies-literature
| S-EPMC8015393 | biostudies-literature
| S-EPMC4364572 | biostudies-literature